Tang, Kwan Ho

SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models

Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 315

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 265

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

Tang, K. H., Li, S., Khodadadi-Jamayran, A., Jen, J., Han, H., Guidry, K., Chen, T., Hao, Y., Fedele, C., Zebala, J. A., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersProtein Tyrosine Phosphatases

Cited by 105

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K. H., Cao, S., Chouitar, J., Wu, J., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 57